Levofloxacin in the treatment of complicated urinary tract infections and acute pyelonephritis

Jessina C McGregor, George P Allen, David T BeardenOregon State University College of Pharmacy, Portland, OR, USAAbstract: Levofloxacin is a widely used fluoroquinolone approved for the treatment of complicated urinary tract infections and acute pyelonephritis. A comprehensive review of the medical...

Full description

Bibliographic Details
Main Authors: Jessina C McGregor, George P Allen, David T Bearden
Format: Article
Language:English
Published: Dove Medical Press 2008-11-01
Series:Therapeutics and Clinical Risk Management
Online Access:http://www.dovepress.com/levofloxacin-in-the-treatment-of-complicated-urinary-tract-infections--a2541
id doaj-cb6273e41a0942eab0655f62590169c7
record_format Article
spelling doaj-cb6273e41a0942eab0655f62590169c72020-11-24T23:54:30ZengDove Medical PressTherapeutics and Clinical Risk Management1176-63361178-203X2008-11-012008Issue 5843853Levofloxacin in the treatment of complicated urinary tract infections and acute pyelonephritisJessina C McGregorGeorge P AllenDavid T BeardenJessina C McGregor, George P Allen, David T BeardenOregon State University College of Pharmacy, Portland, OR, USAAbstract: Levofloxacin is a widely used fluoroquinolone approved for the treatment of complicated urinary tract infections and acute pyelonephritis. A comprehensive review of the medical literature identified five publications evaluating levofloxacin for the treatment of either complicated urinary tract infections or acute pyelonephritis. All trials, although variable in their inclusion criteria and levofloxacin dosing strategies, reported microbiologic, clinical, and safety-related outcomes. High microbiologic eradication rates, ranging from 79.8% to 95.3%, were observed in all studies. Escherichia coli was the most commonly isolated uropathogen. Data on levofl oxacin resistance, both at baseline and after therapy, were limited. Clinical success was observed to range from 82.6% to 93% when measured after the completion of therapy. These clinical and microbiologic results were comparable to the fluoroquinolone comparators in all trials. Insufficient data are available to evaluate the outcomes in any meaningful patient subgroups, including catheterized patients, and those with other specific complicating factors. Levofloxacin was well tolerated in these studies, with headache, gastrointenstinal effects, and dizziness being the most commonly reported adverse events. The published data support the use of levofloxacin in complicated urinary tract infections and acute pyelonephritis. Further trials are necessary to evaluate levofl oxacin within specific patient sub-populations.Keywords: urinary tract infection, pyelonephritis, levofloxacin http://www.dovepress.com/levofloxacin-in-the-treatment-of-complicated-urinary-tract-infections--a2541
collection DOAJ
language English
format Article
sources DOAJ
author Jessina C McGregor
George P Allen
David T Bearden
spellingShingle Jessina C McGregor
George P Allen
David T Bearden
Levofloxacin in the treatment of complicated urinary tract infections and acute pyelonephritis
Therapeutics and Clinical Risk Management
author_facet Jessina C McGregor
George P Allen
David T Bearden
author_sort Jessina C McGregor
title Levofloxacin in the treatment of complicated urinary tract infections and acute pyelonephritis
title_short Levofloxacin in the treatment of complicated urinary tract infections and acute pyelonephritis
title_full Levofloxacin in the treatment of complicated urinary tract infections and acute pyelonephritis
title_fullStr Levofloxacin in the treatment of complicated urinary tract infections and acute pyelonephritis
title_full_unstemmed Levofloxacin in the treatment of complicated urinary tract infections and acute pyelonephritis
title_sort levofloxacin in the treatment of complicated urinary tract infections and acute pyelonephritis
publisher Dove Medical Press
series Therapeutics and Clinical Risk Management
issn 1176-6336
1178-203X
publishDate 2008-11-01
description Jessina C McGregor, George P Allen, David T BeardenOregon State University College of Pharmacy, Portland, OR, USAAbstract: Levofloxacin is a widely used fluoroquinolone approved for the treatment of complicated urinary tract infections and acute pyelonephritis. A comprehensive review of the medical literature identified five publications evaluating levofloxacin for the treatment of either complicated urinary tract infections or acute pyelonephritis. All trials, although variable in their inclusion criteria and levofloxacin dosing strategies, reported microbiologic, clinical, and safety-related outcomes. High microbiologic eradication rates, ranging from 79.8% to 95.3%, were observed in all studies. Escherichia coli was the most commonly isolated uropathogen. Data on levofl oxacin resistance, both at baseline and after therapy, were limited. Clinical success was observed to range from 82.6% to 93% when measured after the completion of therapy. These clinical and microbiologic results were comparable to the fluoroquinolone comparators in all trials. Insufficient data are available to evaluate the outcomes in any meaningful patient subgroups, including catheterized patients, and those with other specific complicating factors. Levofloxacin was well tolerated in these studies, with headache, gastrointenstinal effects, and dizziness being the most commonly reported adverse events. The published data support the use of levofloxacin in complicated urinary tract infections and acute pyelonephritis. Further trials are necessary to evaluate levofl oxacin within specific patient sub-populations.Keywords: urinary tract infection, pyelonephritis, levofloxacin
url http://www.dovepress.com/levofloxacin-in-the-treatment-of-complicated-urinary-tract-infections--a2541
work_keys_str_mv AT jessinacmcgregor levofloxacininthetreatmentofcomplicatedurinarytractinfectionsandacutepyelonephritis
AT georgepallen levofloxacininthetreatmentofcomplicatedurinarytractinfectionsandacutepyelonephritis
AT davidtbearden levofloxacininthetreatmentofcomplicatedurinarytractinfectionsandacutepyelonephritis
_version_ 1716255033896468480